2 active not recruiting, 2 recruiting, 1 enrolling by invitation, 1 withdrawn. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Recruiting 2, Enrolling by invitation 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Diffuse Hemispheric Glioma, H3 G34-mutant: new trials by email Literature Review of Diffuse Hemispheric Glioma, H3 G34-mutant trials Research Report on Diffuse Hemispheric Glioma, H3 G34-mutant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 177Lu-PSMA-617 in People With Gliomas Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI - Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2025-10-27 | 2026-06-04 |
| Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma Nivolumab, Azacitidine (AZA), lumbar puncture - Glioblastoma (GBM), Diffuse Midline Glioma (DMG) | Phase 1 | Enrolling by invitation | Andrew P. Groves | 34 | 2025-06-05 | 2026-10-27 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours Amivantamab - Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 12 | 2024-10-09 | 2026-08-17 |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 6 | 2024-06-14 | 2026-02-17 |
Glioblastoma (4) · Astrocytoma (2) · Glioma (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neoplasms, Neuroepithelial (4) · Neuroectodermal Tumors (4) · Glioma (3) · Astrocytoma (2)
Leukapheresis (2) · Nivolumab (2) · Temozolomide (2) · poly ICLC (2) · Azacitidine (1) · CTLA-4 Antigen (1) · Ipilimumab (1) · Magnetic Resonance Imaging (1) · Magnetic Resonance Spectroscopy (1) · Pluvicto (1) · Specimen Handling (1) · Spinal Puncture (1) · amivantamab (1) · defactinib (1)
Institute of Cancer Research, United Kingdom (2) · Jonsson Comprehensive Cancer Center (2) · Andrew P. Groves (1) · Memorial Sloan Kettering Cancer Center (1)
United States (4) · United Kingdom (2)
Juanita Lopez, MD, PhD (2) · Anthony C Wang (1) · Anthony C Wang, MD (1) · Brandon Imber, MD (1)